Since every molecule is different and no product is like another, we at Coriolis are dedicated to offer the development of a broad range of different product types.
Coriolis develops formulations mainly for biopharmaceutical molecules. Thus, the administration route of choice is often parenteral. We offer the development of formulations tailor-made for intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intracardial, intravitreal, intraocular or intra-articular application, considering the special requirements for each option.
At Coriolis we can develop both, liquid (link to liquid formulation) as well as lyophilized formulations (link to lyophilized formulation). And we can do so for a large variety of different biopharmaceutical molecules, including monoclonal antibodies, antibody-fragments, proteins, peptides, RNAs, DNAs, vaccines, virus-like particles or oncolytic viruses.
Further, we can develop optimal conditions for complex formulations, containing multiple APIs. Having laboratories with the Biosafety level [BSL] 1 and 2, we can also handle certain genetically modified organisms or viruses.
Packaging materials are not only there for transport, they are critical for the stability and efficacy of the therapy. We at Coriolis are experienced and equipped to develop formulations for vials of all formats, syringes, cartridges and other formats including dedicated applicators.